Filing Flows › Interpace Biosciences (IDXG) › Q1 2026 › vs Q1 2025
Interpace Biosciences (IDXG) Q1 2026 vs Q1 2025 (year over year)
Interpace Biosciences's revenue fell $2.5M (-22%) from $11.5M in Q1 2025 to $9.0M in Q1 2026. Gross margin 65.4% against 64.0% (+1.4 pts).
Interpace Biosciences, Q1 2026: revenue $9.0M (-22% year over year), operating margin 12.4%, net earnings $721K, operating cash flow $283K. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Gross margin | 65.4% | 64.0% | +1.4 pts |
| Operating margin | 12.4% | 15.9% | -3.5 pts |
| Net margin | 8.0% | 14.3% | -6.3 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.0M | $11.5M | −$2.5M | -22% |
| Gross profit | $5.9M | $7.4M | −$1.5M | -20% |
| Cost of revenue | $3.1M | $4.1M | −$1.0M | -25% |
| Operating profit | $1.1M | $1.8M | −$706K | -39% |
| Operating expenses | $4.8M | $5.5M | −$760K | -14% |
| Pre-tax earnings | $1.0M | $1.7M | −$642K | -39% |
| Other expense, net | $100K | $164K | −$64K | -39% |
| Research & development | $153K | $177K | −$24K | -14% |
| Sales & marketing | $2.2M | $2.8M | −$637K | -23% |
| General & admin | $2.5M | $2.5M | −$99K | -4% |
| Net earnings | $721K | $1.6M | −$926K | -56% |
| Income tax | $302K | $18K | $284K | 17× |
| Depreciation & amortization | $118K | $95K | $23K | +24% |
| Share-based compensation | $4K | $15K | −$11K | -73% |
| Working capital & other | $560K | $522K | $38K | +7% |
| Operating cash flow | $283K | $1.2M | −$952K | -77% |
Questions
How much did Interpace Biosciences's revenue grow year over year in Q1 2026?
Interpace Biosciences's revenue fell $2.5M (-22%) from $11.5M in Q1 2025 to $9.0M in Q1 2026. Gross margin 65.4% against 64.0% (+1.4 pts).